The role of immunosuppression in recurrence of hepatitis CJohn R Lake
Gastroenterology Division, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 9:S63-6. 2003
..3. Change in the degree of immunosuppression, rather than the absolute amount of immunosuppression, is bad for HCV-infected recipients. 4. Corticosteroid boluses are bad for HCV-infected recipients...
Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives?John R Lake
Gastroenterology Division, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 14:S23-6. 2008
..4. Effective prophylaxis against HBV re-infection can now be accomplished with combination nucleoside/nucleotide anti-virals...
Hot-topic debate on kidney function: renal-sparing approaches are ineffectiveJohn R Lake
Division of Gastroenterology and Hepatology, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 17:S50-3. 2011
..4. The use of CNIs in the early posttransplant period is currently essential. 5. Whether new agents will be able to provide effective immunosuppression as primary immunosuppressives remains to be proven...
Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapyDilip S Nath
Department of Surgery, University of Minnesota Medical School, Minneapolis, 55455, USA
Clin Transplant 20:206-10. 2006
..CONCLUSION: Longer follow-up is needed, but this regimen may represent an alternative to chronic HBIG maintenance therapy...
The impact of MELD allocation on simultaneous liver-kidney transplantationJulie A Thompson
Division of Gastroenterology and Hepatology, 420 Delaware Street SE MMC 36, Minneapolis, MN 55455, USA
Curr Gastroenterol Rep 11:76-82. 2009
..Finally, recommendations regarding who should receive SLK transplants are reviewed...
Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitisJohn R Lake
Gastroenterology Division, University of Minnesota, Minneapolis, Minnesota, USA
Am J Transplant 5:549-57. 2005
..There are clear differences in risk factors for poor outcomes based on underlying liver disease, particularly with regard to the impact of donor age...
Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc groupAndrew D Bostom
Department of Surgery, University of Minnesota, MMC-328 Mayo, Minneapolis 55455, USA
Am J Transplant 2:491-500. 2002
Technique of split-liver transplant for two adult recipientsAbhinav Humar
Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 8:725-9. 2002
Hepatitis B immune globulin for life versus limited use: I favor limited duration of therapyJohn R Lake
Liver Transplantation Program, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 8:S90-1. 2002
Split-liver transplants for two adult recipients: technique of preservation of the vena cava with the right lobe graftAbhinav Humar
Department of Surgery, University of Minnesota, Minneapolis, MN 55455, USA
Liver Transpl 10:153-5. 2004
Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis CRussell H Wiesner
Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Liver Transpl 11:750-9. 2005
..In conclusion, the addition of MMF at discharge to tacrolimus-based immunosuppression is associated with improved long-term outcomes after liver transplantation in patients with and without HCV...
The challenging patient: HCV and alcoholic liver diseaseMichael R Lucey
Department of Medicine, University of Wisconsin, School of Medicine and Public Health, Madison, WI, USA
Liver Transpl 13:S87-8. 2007
Immunosuppression and outcomes of patients transplanted for hepatitis CJohn R Lake
J Hepatol 44:627-9. 2006
Role of tacrolimus in the evolution of liver transplantationRonald W Busuttil
Division of Liver and Pancreas Transplant, Department of Surgery, UCLA School of Medicine, Los Angeles, CA, USA
Transplantation 77:S44-51. 2004
..In the decade since tacrolimus was approved for use in the United States, it has become a widely used immunosuppressant in the field of liver transplantation...
MELD--an imperfect, but thus far the best, solution to the problem of organ allocationJohn R Lake
J Gastrointestin Liver Dis 17:5-7. 2008
Liver transplantation for erythropoietic protoporphyria liver diseaseBrendan M McGuire
Department of Medicine, University of Alabama at Birmingham, 1530 Third Avenue South, Birmingham, AL 35294 0005, USA
Liver Transpl 11:1590-6. 2005
..In conclusion, the 5-year patient survival rate in patients transplanted for EPP liver disease is good, but the recurrence of EPP liver disease appears to diminish long term graft and patient survival...
The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distributionRobert S Brown
Am J Transplant 5:203-4. 2005